Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial.

Febrile Neutropenia Clinical Trial

— ACACIA  

Official title:

Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04698057
• Other study ID #: ACACIA
• Status: Withdrawn
• Phase: Phase 3
• Start date: March 1, 2022
• Est. completion date: June 1, 2025

Study information

• Verified date: March 2022
• Source: Poitiers University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In low risk neutropenic fever in cancer, standard of care is the association of amoxicillin clavulanate and ciprofloxacin. But in this population, the rate of fever related to infection is very low, leading to a overtreatment of the patients. The aim of this study is to validate a descalation of the antibiotherapy with safety concerns.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 1, 2025
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 110 Years

Eligibility

Inclusion Criteria:

• Patient = 18 years old

• Treated for a solid cancer or a hematological malignancy

• Presented with low-risk* febrile neutropenia due to chemotherapy with an expected duration of neutropenia = 7 days

• Neutropenia is defined by an absolute neutrophil count = 500/mm3.

• Fever is defined by temperature = 38.3° or = 38° twice during a 1-hour interval.

• Signing informed consent *Low risk is defined by MASCC score = 21

Exclusion Criteria:

• Hypersensitivity to the active substances: amoxicillin-clavulanic, ciprofloxacin, penicillins, to other quinolones or to one of the excipient

• History of severe immediate hypersensitivity reaction to another beta-lactam

• History of jaunditis/hepatic impairment related to amoxicillin/clavulanic

• Concomitant administration of ciprofloxacin and tizanidine.

• Clinical signs of focal infection including history of untreated dental abscess.

• Signs of sepsis or organ failure.

• Severe immune deficiency other than the current cancer, except controlled-HIV infection

• Gastrointestinal symptoms requiring intravenous treatment (mucositis, vomiting, severe diarrhea...).

• Known aminotransferase serum levels > 5 x normal values.

• Known renal insufficiency defined as creatinine clearance of < 30 mL/min (MDRD).

• Antibiotherapy within 24h before enrollment. Prophylactic use of amoxicillin is an exclusion criterium whereas prophylactic use of trimethoprim-sulfamethoxazole (cotrimoxazole) and penicillin G (Oracilline®) are not and will be considered in the analysis.

• History of infection or colonization due to bacteria resistant to experimental drugs in the previous year

• Can be enrolled in the study only once.

• Patients not benefiting from a Social Security scheme or not benefiting from it through a third party.

• Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergencies

• Pregnant or breastfeeding women, women at age to procreate and not using effective contraception (either hormonal / mechanical : oral, injection, subcutaneous, implantable, intrauterine device, or surgical : tubal ligation, hysterectomy, total ovariectomy).

Related Conditions & MeSH terms

• Febrile Neutropenia
• Fever
• Hyperthermia
• Neutropenia

Intervention

Drug:
• Placebo
The aim of the study is to validate the desescalation of the treatment to stop ciprofloxacin prescription that may not impact the outcome of the patients but add toxicity and antibiotics selection. Placebo will be administred in the experimental arm
• Amoxicillin Clavulanate
Will be administred to all patients
• Ciprofloxacin
Will be administred to patients in the standard of care arm

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Poitiers University Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Success rate	The success rate is defined by the proportion of patients receiving the tested regimen: with resolution of fever =72h after the start of antibiotics (total duration of antibiotics expected : 5 days); AND without any modification of the antibiotic regimen (route, dosage, combination total duration of antibiotics expected : 5 days),; AND without fever recurrence in 48h following the discontinuation of antibiotics (so end of the measure of the main outcome at day 7).	7 days